Basisstatistiken
| LEI | 549300CATCWKUQ6G5854 |
| CIK | 890821 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enveric Biosciences, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| June 1, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Enveric Biosciences, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.01 per share ("Common Stock") Other 553,784 $ 2.1825 $ 1,208,633.58 0.0001381 $ |
|
| June 1, 2026 |
As filed with the Securities and Exchange Commission on May 29, 2026 As filed with the Securities and Exchange Commission on May 29, 2026 Registration No. |
|
| May 29, 2026 |
RESTRICTED STOCK AWARD AGREEMENT ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN Exhibit 10.2 RESTRICTED STOCK AWARD AGREEMENT ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN 1. Grant of Award. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”) for Employees, Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), the Company grants to (the “Participant”) an Award of Restricted Stock in |
|
| May 29, 2026 |
Exhibit 10.1 WITH EXECUTIVE EMPLOYMENT AGREEMENT FORM RESTRICTED STOCK UNIT AWARD AGREEMENT ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN 1. Award of Restricted Stock Units. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”) for Employees, Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), the Company |
|
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2026 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| May 15, 2026 |
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 Product Development Highlights: ● Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial ● Reported additional preclinical data for EB-003 demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways linked |
|
| April 30, 2026 |
Exhibit 99.1 April 30, 2026 Dear Enveric Biosciences, Inc. Stockholder, We are writing to inform you of an important update regarding our 2026 Annual Meeting of Stockholders. After the distribution of our definitive proxy statement, dated April 14, 2026, we identified a typographical error. To ensure you have the most accurate and complete information, we have filed additional definitive proxy mat |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2026 |
Enveric Biosciences Inc. 6,822,225 Shares of Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-295273 PROSPECTUS Enveric Biosciences Inc. 6,822,225 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to an aggregate 6,822,225 shares (the “Shares”) of our common stock, par value $0.01 per share (the “Common Stock”) consisting of (i) 98,000 shares of our Common Stock, (ii) 2,124,223 shares of our |
|
| April 28, 2026 |
April 28, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 27, 2026 |
April 27, 2026 Joseph Tucker, Ph.D. Chief Executive Officer Enveric Biosciences, Inc. 245 First Street, Riverview II, 18th Floor Cambridge MA, 02142 Re: Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed April 23, 2026 File No. 333-295273 Dear Joseph Tucker, Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules |
|
| April 23, 2026 |
As filed with the Securities and Exchange Commission on April 23, 2026 As filed with the Securities and Exchange Commission on April 23, 2026 Registration No. |
|
| April 23, 2026 |
Calculation of Filing Fee Tables S-3 Enveric Biosciences, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward I |
|
| April 20, 2026 |
Exhibit 10.2 EXHIBIT B REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April , 2026, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securiti |
|
| April 20, 2026 |
SERIES J COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 20, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 16, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| April 20, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 16, 2026, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| April 20, 2026 |
PRE-FUNDED COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.1 EXHIBIT A-2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC |
|
| April 20, 2026 |
Exhibit 99.2 Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules $5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass., April 17, 2026 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing n |
|
| April 20, 2026 |
SERIES I COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 20, 2026 |
Exhibit 99.1 Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules $5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants CAMBRIDGE, Mass., April 16, 2026 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neurop |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| April 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 27, 2026 |
Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 Product Development Highlights: ● Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD) ● Identifie |
|
| March 27, 2026 |
SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Exhibit 21.1 SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Subsidiary Jurisdiction of Organization Jay Pharma Inc. Ontario, Canada 1306432 B.C. Unlimited Liability Company British Columbia, Canada 1236567 B.C. Unlimited Liability Company British Columbia, Canada Enveric Biosciences Canada, Inc. British Columbia, Canada MagicMed USA, Inc. Massachusetts, USA Akos Biosciences, Inc. Delaware, USA Enveric |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| February 18, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-293327 PROSPECTUS ENVERIC BIOSCIENCES, INC. Up to 328,802 Shares of Common Stock Underlying the Series G Warrants Up to 328,802 Shares of Common Stock Underlying the Series H Warrants Up to 23,016 Shares of Common Stock Underlying the Placement Agent Warrants This prospectus relates to the issuance by us and the resale by the selling stockholde |
|
| February 17, 2026 |
February 17, 2026 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 245 First Street, Riverview II, 18th Floor Cambridge, MA 02142 Re: Enveric Biosciences, Inc. Registration Statement on Form S-1 Filed February 10, 2026 File No. 333-293327 Dear Joseph Tucker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and |
|
| February 17, 2026 |
February 17, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 10, 2026 |
As filed with the Securities and Exchange Commission on February 9, 2026 As filed with the Securities and Exchange Commission on February 9, 2026 Registration No. |
|
| February 10, 2026 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| February 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 February 6, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| February 6, 2026 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-280721 PROSPECTUS SUPPLEMENT (To Prospectus dated April 17, 2025) Up to $1,346,000 Common Stock We have entered into an at the market offering agreement, or the “ATM Agreement,” with H.C. Wainwright & Co., LLC, or “Wainwright,” acting as sales agent, on April 9, 2025, relating to our shares of common stock, par value $0.01 per share (the “Commo |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 27, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| January 28, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 28, 2026 |
SERIES G COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 28, 2026 |
Exhibit 99.2 Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules CAMBRIDGE, Mass., January 28, 2026 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the clos |
|
| January 28, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2026, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| January 28, 2026 |
328,802 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-280721 PROSPECTUS SUPPLEMENT (To Prospectus dated April 10, 2025) 328,802 Shares of Common Stock We are offering 328,802 shares of our common stock, par value $0.01 per share (the “Common Stock”) to certain institutional investors and accredited investors in a registered direct offering. In a concurrent private placement, we are also selling to |
|
| January 28, 2026 |
SERIES H COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 28, 2026 |
Exhibit 99.1 Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules CAMBRIDGE, Mass., January 28, 2026 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered |
|
| January 9, 2026 |
Exhibit 99.1 |
|
| January 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 January 9, 2026 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| December 31, 2025 |
Enveric Biosciences Inc. 882,627 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-292363 PROSPECTUS Enveric Biosciences Inc. 882,627 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 852,780 shares of our common stock, par value $0.01 per share (“Common Stock”), representing shares issuable upon the exerci |
|
| December 22, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 ENVERIC BIOSCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0.01 per share Other 882,627 $ |
|
| December 22, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Enveric Biosciences, Inc. |
|
| December 22, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| December 22, 2025 |
As filed with the Securities and Exchange Commission on December 22, 2025 As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 11, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 12, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 12, 2025 |
Exhibit 10.1 Enveric Biosciences, Inc. December 11, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Enveric Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per |
|
| December 12, 2025 |
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds Exhibit 99.2 Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds CAMBRIDGE, Mass., December 12, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously anno |
|
| December 12, 2025 |
SERIES E COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 12, 2025 |
SERIES F COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 12, 2025 |
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds Exhibit 99.1 Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds CAMBRIDGE, Mass., December 11, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 11, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 10, 2025 |
Enveric Biosciences Inc. 418,313 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-290580 PROSPECTUS Enveric Biosciences Inc. 418,313 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 404,166 shares of our common stock, par value $0.01 per share (“Common Stock”), representing shares issuable upon the exerci |
|
| December 8, 2025 |
December 8, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 5, 2025 |
As filed with the Securities and Exchange Commission on December 5, 2025 As filed with the Securities and Exchange Commission on December 5, 2025 Registration No. |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIEN |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2025 |
Exhibit 99.1 Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding studies, and receipt of FDA response to pre-IND meeting request. CAMBRIDGE, Ma |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 12, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 23, 2025 |
Exhibit 99.1 Enveric Biosciences Announces Reverse Stock Split Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025 CAMBRIDGE, Mass., October 23, 2025 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 22, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 23, 2025 |
CERTIFICATE OF AMENDMENT AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ENVERIC BIOSCIENCES, INC. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENVERIC BIOSCIENCES, INC. Enveric Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Enveric Biosciences, Inc. 2. The Board of Directors of the C |
|
| October 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 3, 2025 |
X0708 D LIVE 0000890821 Enveric Biosciences, Inc. 245 FIRST STREET RIVERVIEW II 18TH FLOOR CAMBRIDGE MA MASSACHUSETTS 02142 239-302-1707 DELAWARE AMERI Holdings, Inc. SPATIALIZER AUDIO LABORATORIES INC Corporation true Joseph E. Tucker 245 First Street, Riverview II 18th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Chief Executive Officer and Director Kevin M. Coveney 245 Firs |
|
| September 30, 2025 |
September 30, 2025 Joseph Tucker, Ph.D. Chief Executive Officer Enveric Biosciences, Inc. 245 First Street, Riverview II, 18th Floor Cambridge, MA, 02142 Re: Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed September 29, 2025 File No. 333-290580 Dear Joseph Tucker Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer |
|
| September 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 ENVERIC BIOSCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0.01 per share Other 5,019,746 |
|
| September 29, 2025 |
As filed with the Securities and Exchange Commission on September 26, 2025 As filed with the Securities and Exchange Commission on September 26, 2025 Registration No. |
|
| September 18, 2025 |
Exhibit 10.1 Enveric Biosciences, Inc. September 17, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Enveric Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per |
|
| September 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 17, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 18, 2025 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 18, 2025 |
SERIES C COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 18, 2025 |
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds Exhibit 99.1 Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds CAMBRIDGE, Mass., September 17, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry into definitive agreements for the |
|
| September 18, 2025 |
SERIES D COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 18, 2025 |
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds Exhibit 99.2 Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds CAMBRIDGE, Mass., September 18, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously ann |
|
| September 2, 2025 |
Exhibit 99.1 Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA Move aligns with company’s vision to leverage the Greater Boston biotech hub’s scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 CAMBRIDGE, Mass., September 2, 2025 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generati |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 2, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 August 26, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| August 29, 2025 |
Exhibit 99.1 |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 August 29, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| August 14, 2025 |
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Exhibit 99.1 Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric’s differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall performance o |
|
| June 3, 2025 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 29, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2025 |
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Exhibit 99.1 Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Corporate, Business and Product Development Highlights: ● Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds ● Added to suite of intellectual property for EB-003, a neuroplastogen targeting undertreated mental health indications ● Signed two licensing agreements for cannabinoid-C |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| May 14, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| April 16, 2025 |
April 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2025 |
Letter from Marcum LLP, dated April 14, 2025 addressed to the Securities and Exchange Commission. Exhibit 16.1 April 14, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Enveric Biosciences, Inc. Commission File Number 001-38286 Commissioners: We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K dated April 14, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or |
|
| April 14, 2025 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| April 10, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 9, 2025 As filed with the U.S. Securities and Exchange Commission on April 9, 2025 Registration No. 333-280721 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of incorpor |
|
| April 10, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| April 10, 2025 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT April 9, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Enveric Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in th |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2025 |
Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 Product Development Highlights: ● Advanced pre-IND and research activities including confirmation of oral bioavailability and significant brain exposure for EB-003, a novel potential first-in-class neuroplastogenic molecule designed to treat severe mental health di |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2025 |
SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Exhibit 21 SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Subsidiary Jurisdiction of Organization Jay Pharma Inc. Ontario, Canada 1306432 B.C. Unlimited Liability Company British Columbia, Canada 1236567 B.C. Unlimited Liability Company British Columbia, Canada Enveric Biosciences Canada, Inc. British Columbia, Canada MagicMed USA, Inc. Massachusetts, USA Akos Biosciences, Inc. Delaware, USA Enveric Th |
|
| March 28, 2025 |
Exhibit 10.37 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered as of November 7, 2024 (the “Effective Date”), by and between Enveric Biosciences, Inc., a De |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| March 28, 2025 |
Exhibit 10.14 RESTRICTED STOCK AWARD AGREEMENT ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN 1. Grant of Award. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”) for Employees, Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), the Company grants to (the “Participant”) an Award of Restricted Stock in |
|
| March 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Enveric Biosciences, Inc. |
|
| March 24, 2025 |
As filed with the Securities and Exchange Commission on March 24, 2025 As filed with the Securities and Exchange Commission on March 24, 2025 Registration No. |
|
| March 24, 2025 |
Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan Exhibit 10.1 ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN, AS AMENDED The Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Original Plan”), was adopted by the Board of Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), effective as of December 31, 2020 (the “Effective Date”), was amended as of July 14, 2022 and was further amended as of November |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 26, 2025 |
Investor Presentation Q1 2025 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| February 5, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| February 3, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-284277 PROSPECTUS Enveric Biosciences, Inc. 1,229,330 Shares of Common Stock 1,666,666 Series A Warrants to Purchase up to 1,666,666 Shares of Common Stock 1,666,666 Series B Warrants to Purchase up to 1,666,666 Shares of Common Stock 437,336 Pre-Funded Warrants to Purchase 437,336 Shares of Common Stock 3,770,668 Shares of Common Stock Underly |
|
| February 3, 2025 |
Enveric Biosciences Announces Closing of $5 Million Public Offering Exhibit 99.2 Enveric Biosciences Announces Closing of $5 Million Public Offering CAMBRIDGE, Mass., February 3, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its pr |
|
| February 3, 2025 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 30, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| February 3, 2025 |
Enveric Biosciences Announces Pricing of $5 Million Public Offering Exhibit 99.1 Enveric Biosciences Announces Pricing of $5 Million Public Offering CAMBRIDGE, Mass., January 30, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a publ |
|
| January 30, 2025 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockholder Approva |
|
| January 30, 2025 |
Exhibit 1.1 Execution Version December 8, 2024 STRICTLY CONFIDENTIAL Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 Attn: Joseph Tucker, Ph.D., Chief Executive Officer Dear Dr. Tucker: This letter agreement (this “Agreement”) constitutes the agreement between Enveric Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright sh |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. |
|
| January 30, 2025 |
Form of Securities Purchase Agreement Exhibit 10.33 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| January 30, 2025 |
Exhibit 4.14 EXHIBIT A-2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| January 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| January 30, 2025 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockholder Approva |
|
| January 30, 2025 |
January 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 30, 2025 |
Amendment to the Wainwright Engagement Letter, dated January 14, 2025 Exhibit 1.2 Execution Version January 14, 2025 STRICTLY CONFIDENTIAL Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 Attn: Joseph Tucker, Ph.D., Chief Executive Officer Dear Mr. Tucker: Reference is made to the engagement letter (the “Engagement Letter”), dated December 8, 2024, by and between Enveric Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration Statement No. |
|
| January 30, 2025 |
Exhibit 4.17 EXHIBIT A-1 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of inco |
|
| January 21, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENVERIC BIOSCIENCES, INC. Enveric Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Enveric Biosciences, Inc. 2. The Board of Directors of the C |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 17, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| January 21, 2025 |
January 21, 2025 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 Re: Enveric Biosciences, Inc. Registration Statement on Form S-1 Filed January 14, 2025 File No. 333-284277 Dear Joseph Tucker: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding r |
|
| January 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| January 14, 2025 |
As filed with the Securities and Exchange Commission on January 14, 2025 As filed with the Securities and Exchange Commission on January 14, 2025 Registration No. |
|
| January 3, 2025 |
Investor Presentation Q1 2025 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| January 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| December 19, 2024 |
December 19, 2024 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N., Suite 200 Naples, FL 34103 Re: Enveric Biosciences, Inc. Preliminary Proxy Statement on Schedule 14A Filed November 27, 2024 Dear Joseph Tucker: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 22, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIEN |
|
| November 14, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT Pharmaceutical and OTC Cannabinoid Compounds for Treatment of Radiation Dermatitis THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), is made and entered on this 1 |
|
| November 14, 2024 |
ENVB / Enveric Biosciences, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
Exhibit 99.1 Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent protection for a broad range of molecules in its EVM301 portfolio, including five previously unannounced US patents Out-li |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29405E208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 12, 2024 |
Exhibit 99.1 Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales CAMBRIDGE, Mass., November 12, 2024 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedica |
|
| November 12, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
ENVB / Enveric Biosciences, Inc. / AdvisorShares Trust Passive Investment SC 13G/A 1 sch13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 29405E208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to |
|
| September 12, 2024 |
4,900,000 Shares of Common Stock Enveric Biosciences, Inc. Filed Pursuant to Rule 424(b)(4) Registration No. 333-281934 PROSPECTUS 4,900,000 Shares of Common Stock Enveric Biosciences, Inc. This prospectus relates to the offer and resale of up to 4,900,000 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock bein |
|
| September 10, 2024 |
September 10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 9, 2024 |
September 9, 2024 Joseph Tucker, Ph.D Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N , Suite 200 Naples, FL 34103 Re: Enveric Biosciences, Inc. Registration Statement on Form S-1 Filed September 4, 2024 File No. 333-281934 Dear Joseph Tucker Ph.D: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 4 |
|
| September 4, 2024 |
As filed with the Securities and Exchange Commission on September 4, 2024 As filed with the Securities and Exchange Commission on September 4, 2024 Registration No. |
|
| September 4, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| August 22, 2024 |
Investor Presentation Q3 2024 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| August 12, 2024 |
Exhibit 99.1 Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe mental health disorders Announced preclinical results confirming oral bioavailability and significant brain exposure of EB-003, supporting expedited development strateg |
|
| August 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| July 15, 2024 |
Exhibit 99.1 Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement Aries to clinically develop and market Enveric’s patented product for radiation dermatitis CAMBRIDGE, Mass., July 15, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Ari |
|
| July 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 10, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| July 12, 2024 |
July 12, 2024 Joseph Tucker, Ph.D. Chief Executive Officer Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 Re: Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed July 8, 2024 File No. 333-280721 Dear Joseph Tucker Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regar |
|
| July 8, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 8, 2024 As filed with the U.S. Securities and Exchange Commission on July 8, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of incorporation or organization) (I. |
|
| July 8, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| May 29, 2024 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 17, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
Exhibit 99.1 Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners that upon en |
|
| May 3, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-257690 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) 458,000 Shares of Common Stock We are offering 458,000 shares of our common stock, par value $0.01 per share, at a deemed offering price of $0.94 per share directly to certain investors in a registered direct offering pursuant to this prospectus supplement, the accompanying prospec |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 3, 2024 |
Exhibit 10.1 ENVERIC BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of May 3, 2024 (“Execution Date”), by and between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and the investor set forth on the signature page hereto (the “Investor”). WHEREAS, on December 28, 2023, the Company entered into warrant |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2024 |
Exhibit 14 ENVERIC BIOSCIENCES, INC. CORPORATE CODE OF CONDUCT AND ETHICS AND WHISTLEBLOWER POLICY Effective December 31, 2020 INTRODUCTION Enveric Biosciences, Inc. (“we” or the “Company”) has adopted this Corporate Code of Conduct and Ethics and Whistleblower Policy (the “Code”) to provide our associates, as defined below, with a clear understanding of the principles of business conduct and ethi |
|
| March 26, 2024 |
Exhibit 19 Enveric Biosciences Inc. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) provides guidelines to all employees and officers of Enveric Biosciences, Inc. and its affiliates (the “Company”) as well as members of the Company’s Board of Directors (the “Directors”) with respect to transactions in the Company’s securities, and codifies the Company’s standards on trading and e |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| March 26, 2024 |
Exhibit 97 ENVERIC BIOSCIENCES, INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Enveric Biosciences, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability. The Board has therefore adopted this Clawback Policy (the “Policy”), which provides for the rec |
|
| March 26, 2024 |
Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 Product Development Highlights: ● Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. ● Started IND-enab |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2024 |
Exhibit 99.1 Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease Second biotechnology company to potentially out-license novel compounds from Enveric’s portfolio of assets with possible significant milestone payments and royalties CAMBRIDGE, Mass., March 19, 2024 – E |
|
| March 11, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-257690 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) 228,690 Shares of Common Stock We are offering 228,690 shares of our common stock, par value $0.01 per share, at a deemed offering price of $1.41 per share directly to certain investors in a registered direct offering pursuant to this prospectus supplement, the accompanying prospec |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2024 |
Exhibit 10.1 ENVERIC BIOSCIENCES. INC. COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of March 8, 2024, by and between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and the investor set forth on the signature page hereto (the “Investor”). WHEREAS, on December 28, 2023, the Company entered into warrant exercise induceme |
|
| February 29, 2024 |
Exhibit 99.1 Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass., February 29, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicate |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 29, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 21, 2024 |
Exhibit 99.1 Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders Novel compounds protected under Enveric’s intellectual property portfolio provide potential licensing opportunities and non-dilutive revenue streams. CAMBRIDGE, Mass., February 21, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company” |
|
| February 14, 2024 |
US29405E2081 / ENVERIC BIOSCIENCES INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| February 6, 2024 |
SC 13G/A 1 ea192881-13ga2intraenveric.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29405E208 (CUSIP Number) December 31, 2023 (Date of Event Which Re |
|
| February 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29405E208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 24, 2024 |
Enveric Biosciences Inc. 2,244,000 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-276473 Enveric Biosciences Inc. 2,244,000 Shares of Common Stock This prospectus relates to the resale of up to 2,244,000 shares of Enveric Biosciences, Inc. (the “Company,” “we,” or “us”) common stock, par value $0.01 per share, by the selling stockholders named in this prospectus or its permitted transferees. The shares of common s |
|
| January 19, 2024 |
January 19, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 16, 2024 |
United States securities and exchange commission logo January 16, 2024 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. |
|
| January 11, 2024 |
As Filed with the Securities and Exchange Commission on January 11, 2024 As Filed with the Securities and Exchange Commission on January 11, 2024 Registration No. |
|
| January 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 ENVERIC BIOSCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0.01 per share Other 2,244,000 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| January 3, 2024 |
Exhibit 99.1 Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass., January 3, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| December 29, 2023 |
Exhibit 10.1 December 28, 2023 [Name and address of warrant holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants To Whom It May Concern: Enveric Biosciences, Inc. (the “Company”) is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of (i) the Common Stock purchase warrants issued to you on or abo |
|
| December 29, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 29, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market CAMBRIDGE, Mass., December 29, 2023 (BUSINESS WIRE) – Enveric Biosciences (NASDAQ: ENVB (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for th |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 28, 2023 |
Exhibit 99.1 Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass., December 28, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 27, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 27, 2023 |
Exhibit 99.1 Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 The ongoing GLP Safety and Toxicology Program of EB-373 is thus far proceeding on time with favorable results CAMBRIDGE, Mass., December 27, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuro |
|
| December 6, 2023 |
1,279,880 Shares of Common Stock Enveric Biosciences, Inc. PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-275380 1,279,880 Shares of Common Stock Enveric Biosciences, Inc. This prospectus relates to the offer and resale of up to 1,279,880 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock bein |
|
| December 5, 2023 |
Exhibit 99.1 Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds Three novel neuroplastic compounds identified with plans to advance one into expedited preclinical development in 2024 CAMBRIDGE, Mass., December 5, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Comp |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| December 4, 2023 |
December 4, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 1, 2023 |
As filed with the Securities and Exchange Commission on December 1, 2023 As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. |
|
| November 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 29, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 29, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives Expands intellectual property portfolio with composition of matter and methods of use claims governing Enveric’s EVM301 Series of drug candidates CAMBRIDGE, Mass., November 29, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company |
|
| November 22, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 21, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 16, 2023 |
United States securities and exchange commission logo November 16, 2023 Joseph Tucker Chief Executive Officer Enveric Biosciences, Inc. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIEN |
|
| November 13, 2023 |
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results Exhibit 99.1 Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results EVM-301 Series ● Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric’s EVM301 Series of candidates targeting the treatment of mental health disorders ● Announced AI-powered drug candidate generat |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ENVERIC BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2023 |
Exhibit 10.43 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of November 3, 2023, is made by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inve |
|
| November 8, 2023 |
As filed with the Securities and Exchange Commission on November 7, 2023 As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. |
|
| November 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| November 8, 2023 |
Exhibit 10.44 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 3, 2023, is entered into by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherw |
|
| November 6, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 3, 2023, is entered into by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwi |
|
| November 6, 2023 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of November 3, 2023, is made by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inves |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2023 |
Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended Exhibit 10.1 ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN, AS AMENDED The Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Original Plan”), was adopted by the Board of Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), effective as of December 31, 2020 (the “Effective Date”), was amended as of July 14, 2022 and was further amended as of November |
|
| October 31, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin Expands its intellectual property portfolio with composition of matter claims governing lead clinical candidate, EB-373, a psilocin prodrug being developed for the treatment of depression and anxiety disorders. CAMBRIDGE, Mas |
|
| October 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 20, 2023 |
Exhibit 99.1 Enveric Biosciences to Present at the Centurion One 5th Global Summit CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass., October 20, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatm |
|
| October 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 20, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 18, 2023 |
Exhibit 99.1 Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373 CAMBRIDGE, Mass., October 18, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or t |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 18, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 11, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit Presentations highlight research involving Enveric’s EVM301 Series of non-hallucinogenic neuroplastogens and the company’s lead product candidate, EB-373 CAMBRIDGE, Mass., October 11, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company |
|
| October 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 3, 2023 |
Exhibit 99.1 Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual property estate CAMBRIDGE, Mass., October 3, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), |
|
| October 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 3, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
